
# **DIC - Disseminated Intravascular Coagulation**



Balance exists between activation of the clotting and clot dissolution

The fibrinolytic pathway

# Activators: Urokinase-type plasminogen activator Tissue-type plasminogen activator Inhibitors: Plasminogen activator inhibitors (PAI-1 and PAI-2) Plasmin Inhibitors: Alpha-1 antitrypsin Alpha-2-antiplasmin Thrombin-activatable fibrinolysis inhibitor Fibrin degredation products (D-dimer, others)

Thrombin generation is normally restricted to the site of injury – the multiple natural anti-thrombotic pathways in the blood tightly regulate thrombin generation.

When these pathways are overwhelmed by production of thrombin, thrombin may circulate and lead to DIC.

The widespread deposition of fibrin results in tissue ischaemia and consumption of platelets, fibrinogen prothrombin and factors V and VIII, which in turn may cause bleeding – in acute DIC it is this picture which predominates.

The major initiating factors for DIC are:

- Extensive vascular injury exposing tissue thromboplastin
- Enhanced expression of tissue thromboplastin by monocytes in response to endotoxin and various cytokines

The major features of DIC are:

- Exposure of blood to procoagulants eg tissue thromboplastin and Ca procoagulant
- Formation of fibrin
- Fibrinolysis
- Depletion of clotting factors
- End-organ damage

### **Causes**

- Sepsis
- Trauma and extensive surgery
- Malignancy
- Obstetric complications, eg
  - Amniotic fluid embolism
  - Abruptio placentae
- Miscellaneous
  - Acute haemolytic transfusion reactions

- Paroxysmal nocturnal haemoglobinuria
- Rattlesnake bites!
- Heat-stroke
- o Rhabdomyolysis
- o ARDS

## **Blood Tests**

- Low platelets
- ↑ aPTT ↑ PT
- ↑ FDP / d-dimer

# **Prognosis**

40 - 80% in patients with severe sepsis, trauma or burns

### **Treatment**

Treat underlying cause!!

### Others:

- Platelet transfusion and FFP. Pts with DIC bleed because of thrombocytopaenia and coagulation factor deficiencies. There is no evidence to support administration of platelets or clotting factors in patients who are not bleeding or at high risk of bleeding. However, treatment is justified in patients who have serious bleeding or are at high risk (eg after extensive surgery).
- **Heparin** no evidence to support its use